# A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation

> **NCT06297629** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Allogeneic Stem Cell Transplantation

## Interventions

- **DRUG:** ASTX727
- **DRUG:** Donor Lymphocyte Infusion

## Key facts

- **NCT ID:** NCT06297629
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-07-01
- **Primary completion:** 2024-07-11
- **Final completion:** 2024-07-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Abandoned
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297629

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297629, "A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06297629. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*